Leptomeningeal metastasis (LM) is one of the serious complications of advanced non-small cell lung cancer (NSCLC), although the incidence is not high, the clinical symptoms are severe and the prognosis is poor. LM is prone to occur in patients with positive driver gene than negative. At present, the treatment of LM mainly includes molecular targeted therapy, systemic chemotherapy, whole brain radiotherapy, intrathecal chemotherapy and immunotherapy. Although there are many treatments, the efficacy of LM is still unsatisfactory. This article reviews the drug therapy of sensitive driver gene positive NSCLC LM.
【中文题目：敏感驱动基因阳性非小细胞肺癌脑膜转移 药物治疗的管理】 【中文摘要：脑膜转移（leptomeningeal metastasis, LM）是晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）严重并发症之一，虽然发生率不高，但临床症状表现严重，预后差。驱动基因阳性NSCLC较驱动基因阴性患者更容易发生LM。目前，LM的治疗方法主要包括分子靶向治疗、系统化疗、全脑放疗、鞘内化疗及免疫治疗等。尽管治疗手段很多，但LM的疗效仍不令人满意。本文就敏感驱动基因阳性NSCLC LM的药物治疗方面作一综述。】 【中文关键词：肺肿瘤；脑膜转移；驱动基因阳性；药物治疗】.
Keywords: Driver gene positive; Drug therapy; Leptomeningeal metastasis; Lung neoplasms.